Team Elite Genetics

In August 2026, Team Elite Genetics concentrated 78.61% of sales in Flower, where year-over-year declined 49.35% while month-over-month rose 5.01%, and held 13.27% in Concentrates with a 36.18% year-over-year drop and a 19.10% month-over-month lift; meanwhile, Vapor Pens at 5.72% contracted 72.27% year-over-year and 11.51% month-over-month, as Pre-Roll at 2.39% fell 74.52% year-over-year but increased 22.92% month-over-month. With an average price down 8.98% year-over-year to $40.29 and Flower ranked 46 in California, the mix implies reliance on a single category is amplifying overall brand sales decline of 51.46% year-over-year, while selective month-over-month rebounds in Flower, Concentrates, and Pre-Roll offer incremental stabilization points against a Vapor Pens drag.

The pattern suggests the brand’s positioning is skewed toward value-sensitive Flower and higher-ticket Concentrates, evidenced by Flower’s 39.90 average price alongside a 5.01% month-over-month uptick and Concentrates’ 19.10% month-over-month growth despite a 36.18% year-over-year decline; in contrast, Vapor Pens’ 72.27% year-over-year fall and 11.51% month-over-month slide mark an underperforming format relative to categories showing recovery. Given Flower’s 78.61% share and a 46 rank in California, the brand’s near-term positioning hinges on defending Flower share while shifting marginal emphasis toward Concentrates and opportunistic Pre-Roll (22.92% month-over-month growth), implying a pragmatic reallocation away from Vapor Pens until price and velocity converge with the broader 8.98% brand-level price reset.